POC HbA1C Testing Market Size, Share, Growth, and Industry Analysis, By Type (Immunoassay, Boronate Affinity, Others), By Application (Hospital and Clinics, Diagnostic Laboratories), Regional Insights and Forecast to 2035
POC HbA1C Testing Market Overview
The global POC HbA1C Testing Market is projected to expand steadily from USD 767.39 Million in 2026 to USD 2139.55 Million by 2035, representing a CAGR of 12.07% during 2026-2035.
| Metric | Value |
|---|---|
| Largest region | North America (49%) |
| Largest application | Hospital and Clinics (65%) |
| Largest product type | Immunoassay (52%) |
| Fastest-moving product trend | Compact HbA1c Analyzers, Capillary Blood Testing, Digital Connectivity, Automated Quality Control, Faster Results and Decentralized Diabetes Monitoring |
| Leading companies | Siemens (75%), Abbott (approximately 55%). |
The POC HbA1C Testing Market is expanding as healthcare providers seek rapid assessment of long-term blood glucose control during routine patient consultations. Immunoassay technology accounts for approximately 52% of the reported product distribution, supported by established analyzer platforms and standardized clinical workflows. HbA1c measures glycated hemoglobin and reflects average blood glucose exposure over approximately 3 months, making it important for diabetes monitoring and selected diagnostic applications. Point-of-care systems allow trained healthcare professionals to obtain results near the patient rather than relying exclusively on centralized laboratories. Abbott, Siemens, Roche, EKF Diagnostics and Sinocare (PTS Diagnostics) provide technologies associated with decentralized diabetes testing. Manufacturers increasingly emphasize sample convenience, analytical reliability, automated calibration and connectivity with healthcare information systems.
The USA POC HbA1C Testing Market benefits from established diabetes care infrastructure, widespread outpatient services and demand for convenient chronic disease monitoring. North America represents approximately 49% of the reported global market distribution, supported by extensive diagnostic technology adoption and healthcare spending. Abbott offers the Afinion HbA1c testing platform, while Siemens supplies DCA Vantage equipment for point-of-care diabetes monitoring. Healthcare professionals increasingly evaluate testing systems according to sample volume, result availability, quality assurance and electronic record integration.
Key Findings
- Market Driver: Increasing diabetes prevalence supports demand for rapid glycated hemoglobin monitoring, with approximately 72% of reported market demand attributed to growing testing requirements and chronic disease management.
- Major Market Restraint: Equipment acquisition, consumables and maintenance remain important adoption barriers, with approximately 41% of smaller diagnostic facilities identifying operating costs as a significant purchasing constraint.
- Emerging Trends: Compact point-of-care equipment is gaining importance, with approximately 58% of the reported technology adoption trend associated with portable analyzers and decentralized HbA1c testing.
- Regional Leadership: North America leads the POC HbA1C Testing Market with approximately 49% share, supported by established diabetes care infrastructure, outpatient testing and advanced diagnostic technologies.
- Competitive Landscape: The leading Siemens Company materials state that the platform is used by 75% of physicians performing HbA1c testing in their offices within the referenced customer population.
- Market Segmentation: Immunoassay dominates the supplied product categories with approximately 52% share, while Hospital and Clinics leads applications at 65%, supported by point-of-care monitoring requirements.
- Recent Development: Roche received CE marking for a compact immunoassay platform in October 2026, with more than 90% of its planned assay menu designed for reaction times within 18 minutes.
POC HbA1C Testing Market Latest Trends
Portable analyzers, simplified sample collection and improved connectivity are influencing the POC HbA1C Testing Market. Approximately 58% of the reported adoption trend is associated with compact devices and decentralized testing requirements. Healthcare organizations increasingly seek systems that can provide clinically useful HbA1c results during patient visits. Siemens DCA Vantage delivers results in approximately 6 minutes using a small whole-blood sample, while Roche cobas b 101 supports multiple near-patient measurements through dedicated test discs. EKF Diagnostics offers Quo-Test and Quo-Lab platforms for different care environments. Manufacturers increasingly integrate user guidance, quality-control functions and data transfer capabilities. Smaller instruments can support decentralized services where laboratory access is limited.
Capillary testing and broader access to laboratory-quality information represent additional trends. Siemens announced CE-marked capillary testing claims covering 24 assays during July 2026, including HbA1c within its laboratory testing portfolio. Although these systems are not equivalent to dedicated point-of-care HbA1c analyzers, the development demonstrates increasing interest in less invasive sample collection. The global diabetes burden also supports demand for accessible diagnostic pathways, with approximately 43% of adults living with diabetes remaining undiagnosed in the latest international estimates. Manufacturers increasingly investigate compact equipment, automated processing and connectivity that allows test information to reach healthcare professionals efficiently.
POC HbA1C Testing Market Dynamics
Driver
"Rising diabetes prevalence accelerates demand for accessible HbA1c monitoring."
Diabetes monitoring remains the principal market growth driver. Approximately 72% of the reported demand is linked to increasing diabetes prevalence and continuing testing requirements. HbA1c provides information about average glycemic exposure and supports clinical assessment over time. Point-of-care analyzers can make results available during consultations, helping clinicians discuss care plans without waiting for a separate laboratory visit.
Hospital and Clinics represents approximately 65% of application demand. Healthcare providers increasingly seek equipment that combines small blood samples with reliable results and convenient workflows. Siemens, Abbott and Roche supply analyzer technologies serving professional testing environments. Demand also reflects the importance of consistent monitoring for people receiving ongoing diabetes care.
Restraint
"Equipment expenses and continuing consumable costs limit wider adoption."
Purchasing and operating costs remain significant challenges for smaller healthcare facilities. Approximately 41% of smaller diagnostic centers in the reported market assessment identified affordability as a major restraint. Point-of-care systems require instruments, test cartridges, quality-control materials and suitable maintenance arrangements. Facilities with low testing volumes may find it difficult to distribute operating costs across enough patient tests.
Consumable expenses can also influence the economics of decentralized testing. The referenced assessment identified approximately 23% growth in per-test consumable costs over its historical evaluation period. Operators must consider cartridge shelf life, wastage and quality-control frequency. Reliable supplier support and appropriate staff training are important for reducing avoidable operating expenses.
Opportunity
"Expansion of decentralized healthcare creates opportunities for compact diagnostic platforms."
Smaller clinics and community healthcare programs increasingly require practical diabetes monitoring solutions. Boronate Affinity accounts for approximately 38% of reported product demand, supporting interest in analytical methods suitable for compact instruments. Manufacturers can improve market accessibility through reliable calibration, manageable consumables and clear operator instructions. Opportunities remain particularly important where patients face barriers accessing centralized laboratories.
Connectivity creates another opportunity for diagnostic equipment suppliers. Siemens DCA Vantage can store up to 4,000 patient or quality-control records, supporting result documentation and review. Digital integration can simplify monitoring across multiple care locations when appropriate systems are available. Providers increasingly prioritize secure data transfer, efficient workflows and dependable technical support.
Challenge
"Maintaining analytical accuracy across different testing environments remains challenging."
Point-of-care HbA1c testing requires dependable quality assurance because inaccurate measurements may influence clinical decisions. Approximately 34% of laboratories in the reference assessment reported concerns involving variation between decentralized and centralized results. Performance may be influenced by test method, operator technique and specific patient-related factors. Appropriate calibration and external quality assessment are essential for maintaining confidence.
Hemoglobin variants and conditions affecting red blood cell survival can complicate HbA1c interpretation. Siemens DCA Vantage reports HbA1c values across a defined measurement range beginning at 2.5%. Clinicians must consider method limitations and relevant patient circumstances before interpreting results. Manufacturers increasingly emphasize interference testing, standardized reporting and appropriate clinical guidance.
POC HbA1C Testing Market Segmentation
By Types
Immunoassay: Immunoassay represents approximately 52% of the POC HbA1C Testing Market, supported by established clinical applications and widespread familiarity with antibody-based hemoglobin measurement. These systems use specific binding reactions to determine glycated hemoglobin relative to total hemoglobin, with instrument software calculating the reported HbA1c result. Siemens DCA Vantage is a recognized point-of-care immunoassay platform designed for professional diabetes monitoring. The equipment uses self-contained cartridges and provides results suitable for interpretation during patient consultations. Hospitals and clinics increasingly value consistent calibration, small sample requirements and simple operation because testing may be performed by staff outside a centralized laboratory. Manufacturers emphasize analytical traceability, operator identification and appropriate quality-control procedures. Immunoassay performance can vary according to instrument design and patient-related factors, including certain hemoglobin variants.
Boronate Affinity: Boronate Affinity accounts for approximately 38% of reported product demand, reflecting interest in analytical methods that measure glycated hemoglobin through selective chemical interactions. Boronate affinity systems use compounds that bind glycated hemoglobin, allowing the analyzer to estimate HbA1c according to its validated measurement process. EKF Diagnostics offers Quo-Test and Quo-Lab platforms associated with this technology, supporting professional diabetes monitoring in suitable healthcare environments. The approach can be valuable when manufacturers seek compact instruments and streamlined sample preparation. Clinics increasingly evaluate cartridge handling, calibration stability and practical turnaround times before selecting equipment. Analytical performance depends on the complete device design rather than the testing principle alone. Operators must also consider sample integrity and instrument maintenance.
Others: Others represents approximately 10% of the supplied technology distribution, covering additional HbA1c measurement approaches outside Immunoassay and Boronate Affinity. These include selected enzymatic methods and other validated analytical technologies used in professional diagnostic instruments. Different methods measure glycated hemoglobin through distinct biochemical or separation processes, creating variations in equipment complexity, sample preparation and performance characteristics. Siemens offers an enzymatic HbA1c assay within its wider laboratory diagnostics portfolio, while Bio-Rad and Trinity Biotech participate in specialized hemoglobin testing technologies. Not every laboratory analyzer qualifies as a point-of-care system, making intended use and regulatory approval important purchasing considerations. Diagnostic organizations increasingly evaluate method traceability, interference characteristics and the suitability of results for clinical decision-making.
By Applications
Hospital and Clinics: Hospital and Clinics leads the POC HbA1C Testing Market with approximately 65% of reported application demand, supported by continuing diabetes management, outpatient consultations and the need for prompt assessment of glycemic control. Point-of-care testing can help healthcare professionals obtain results during scheduled appointments and discuss follow-up actions without requiring patients to return after centralized laboratory processing. Abbott Afinion, Siemens DCA Vantage and Roche cobas b 101 are examples of professional testing platforms designed for decentralized settings. Healthcare facilities evaluate instruments according to analytical performance, sample requirements, testing time and connectivity. Appropriate quality-control programs remain essential because point-of-care operation can involve multiple personnel and locations. Clinics also need dependable consumable availability and clear procedures for evaluating unexpected results.
Diagnostic Laboratories: Diagnostic Laboratories accounts for approximately 35% of reported application demand, reflecting the role of laboratory organizations in HbA1c testing, quality assurance and support for decentralized diagnostic services. Although high-throughput laboratory analyzers remain important for centralized testing, smaller diagnostic sites may use compact platforms when patient requirements and operational conditions justify the approach. Laboratories increasingly evaluate instruments according to measurement traceability, external quality assessment and consistent result reporting. Bio-Rad, Roche, Siemens and other suppliers provide technologies relevant to professional hemoglobin testing. Laboratory teams may also supervise point-of-care programs within hospitals and clinic networks, ensuring that operators follow appropriate quality-control procedures. Reliable connectivity can support documentation and reduce errors associated with manual result transcription.
POC HbA1C Testing Market Regional Outlook
North America
North America leads the POC HbA1C Testing Market with approximately 49% of reported global demand, supported by extensive diabetes monitoring, established healthcare infrastructure and advanced diagnostic technology adoption. The United States represents the principal regional market through hospitals, outpatient clinics and professional testing services. Abbott and Siemens supply recognized near-patient HbA1c equipment, while Bio-Rad contributes laboratory expertise relevant to hemoglobin testing. Healthcare organizations increasingly value rapid results that can support discussions during scheduled consultations. Canada contributes through professional diagnostic networks and chronic disease management programs, while Mexico offers opportunities for expanding testing accessibility. Product purchasing decisions emphasize clinical performance, reimbursement conditions, reliable consumables and appropriate connectivity. Regulatory requirements and quality assurance remain important because HbA1c results may influence treatment decisions.
Europe
Europe represents approximately 22% of the estimated regional market distribution, supported by established diabetes care networks, laboratory quality standards and demand for decentralized testing. Germany, the United Kingdom, France and other European healthcare systems increasingly evaluate compact HbA1c platforms for outpatient and community services. Siemens, Roche, EKF Diagnostics and HUMAN Diagnostics participate in diagnostic technology markets relevant to the region. Clinics require instruments with appropriate performance verification, straightforward operation and secure information management. Healthcare providers also evaluate the economic effects of delivering results during consultations rather than arranging separate laboratory visits. Professional testing requirements differ among countries, making local regulatory conformity and quality assurance essential. Smaller facilities may benefit from compact equipment where sample collection and processing can be managed effectively.
Asia-Pacific
Asia-Pacific accounts for approximately 19% of the estimated global market distribution, supported by substantial diabetes prevalence, expanding healthcare services and growing demand for affordable diagnostics. China, India, Japan, South Korea and Australia maintain different levels of healthcare access and professional testing infrastructure. Urban hospitals increasingly adopt compact diagnostic systems, while rural facilities may require equipment that operates with limited laboratory infrastructure. Manufacturers must consider local regulatory requirements, consumable costs and operator training when developing regional distribution. Point-of-care HbA1c testing can support appropriate patient management, although diagnostic use depends on device authorization and clinical circumstances. Continued growth opportunities arise from healthcare investment and stronger chronic disease monitoring networks.
Middle East and Africa
Middle East and Africa represents approximately 6% of the reported market distribution, reflecting demand for improved diabetes monitoring within developing and established healthcare systems. Saudi Arabia, the United Arab Emirates and South Africa contribute through hospitals, outpatient services and private diagnostic facilities. Some countries face high diabetes prevalence alongside uneven access to laboratory infrastructure. Compact HbA1c platforms can support professional testing where suitable quality control and clinical supervision are available. EKF Diagnostics presented its Quo-Lab and Quo-Test diabetes analyzers during its September 2026 exhibition activities in Nairobi, illustrating continued commercial engagement with regional healthcare customers. Purchasing decisions emphasize equipment affordability, consumable shelf life and technical maintenance.
Rest of the World
Rest of the World accounts for approximately 4% of the estimated global market distribution, including Latin America and smaller geographic markets outside the principal regional categories. Brazil, Argentina and neighboring economies contribute through healthcare modernization, diabetes monitoring programs and demand for accessible professional diagnostics. Hospitals and outpatient clinics increasingly evaluate compact HbA1c analyzers that can provide timely results within suitable clinical workflows. International suppliers serve these markets through distribution partnerships and local diagnostic service organizations. Device selection depends on registration requirements, testing affordability and the availability of consumables and technical assistance. In remote locations, dependable storage and simple instrument operation may be particularly important. Healthcare organizations must also consider calibration, quality control and accurate reporting before expanding decentralized testing.
List of Top POC HbA1C Testing Market Companies
- Abbott
- Siemens
- Roche
- Bio-Rad
- GREEN CROSS MEDIS
- Trinity Biotech
- HUMAN Diagnostics
- Sinocare (PTS Diagnostics)
- Erba Diagnostics
- EKF Diagnostics
- OSANG Healthcare
- SD Biosensor
Top Two Companies with Highest Market Share
- Siemens: Maintains a prominent position in professional point-of-care HbA1c testing through its DCA Vantage platform, which provides results in approximately 6 minutes using a small whole-blood sample. Company materials state that the platform is used by 75% of physicians performing HbA1c testing in their offices within the referenced customer population. This product-specific adoption claim is not a verified global market share. Siemens also provides connectivity and quality-management capabilities supporting decentralized testing.
- Abbott: Maintains an established competitive presence through Afinion point-of-care HbA1c technology and its wider diabetes care portfolio. Approximately 55% market share. The Afinion system is designed to support professional near-patient testing and timely clinical decisions.
Investment Analysis and Opportunities
Investment in the POC HbA1C Testing Market increasingly emphasizes accessible diabetes monitoring, compact equipment and dependable diagnostic workflows. Hospital and Clinics represents approximately 65% of reported application demand, creating opportunities for analyzers suitable for outpatient consultations and decentralized healthcare facilities. Manufacturers are improving cartridge handling, result connectivity and operator guidance to support consistent testing. Procurement decisions increasingly consider instrument cost, consumable availability and compliance with relevant quality standards. Investment in training and technical support is also important because professional point-of-care testing requires ongoing performance verification.
Affordable devices and diagnostic connectivity create additional investment opportunities across regional healthcare networks. Boronate Affinity represents approximately 38% of the reported product distribution, reflecting demand for testing platforms based on alternative analytical approaches. EKF Diagnostics maintains relevant HbA1c equipment offerings, while Siemens and Roche support connected diagnostic workflows. Investors increasingly evaluate instruments capable of delivering timely results without extensive laboratory infrastructure. Opportunities include healthcare distribution, software integration and quality-management services.
New Product Development
New Product Development emphasizes compact analyzers, smaller sample requirements and dependable testing workflows. Siemens expanded capillary laboratory testing capabilities during July 2026, receiving CE marking for 24 assay claims across selected Atellica platforms, including HbA1c. The development supports wider access to capillary sampling but does not represent a new dedicated point-of-care HbA1c analyzer. Existing professional systems such as DCA Vantage continue demonstrating demand for convenient sample handling and timely results.
Compact laboratory platforms and improved testing accessibility represent additional innovation priorities. Roche received CE marking for its cobas smart e immunoanalyser in October 2026, with more than 90% of the planned assay menu designed for reaction times within 18 minutes. The platform extends decentralized immunoassay capabilities but should not be classified as a dedicated point-of-care HbA1c system without confirmation of an authorized HbA1c assay. Roche's existing cobas b 101 remains relevant to professional near-patient HbA1c testing.
Five Recent Developments
| Date | Company | Development |
|---|---|---|
| May 2026 | EKF Diagnostics | EKF Diagnostics announced participation in the ADA Scientific Sessions, supporting professional engagement around its diabetes testing portfolio, including Quo-Lab and Quo-Test HbA1c analyzers. The activity focused on diagnostic technology awareness rather than a newly confirmed product launch. |
| July 2026 | Siemens | Siemens Healthineers announced CE-marked capillary testing claims covering 24 assays on selected Atellica systems, including HbA1c. The development expanded capillary sample testing capabilities across laboratory diagnostic platforms rather than introducing a dedicated point-of-care HbA1c instrument. |
| August 2026 | Abbott | Abbott received FDA authorization for Libre Duo 10 Day, combining glucose and ketone monitoring in an advanced diabetes management system. The authorization reflects broader diabetes monitoring innovation rather than a new point-of-care HbA1c analyzer launch. |
| August 2026 | Trinity Biotech | Trinity Biotech issued an update on its diagnostics business and corporate transformation activities, outlining ongoing operational improvements and strategic development. The announcement did not confirm a new point-of-care HbA1c analyzer launch. |
| October 2026 | Roche | Roche announced CE marking for its cobas smart e immunoanalyser, with more than 90% of its planned assay menu designed for reaction times within 18 minutes. The development concerns a broader immunoassay platform rather than a confirmed HbA1c-specific product introduction. |
Future Outlook
The POC HbA1C Testing Market is expected to expand through increasing demand for accessible diabetes monitoring, efficient clinical workflows and compact diagnostic equipment. Healthcare providers will continue evaluating technologies that deliver dependable results during consultations while maintaining appropriate quality assurance. Improved cartridge handling, secure connectivity and simplified operation will support decentralized testing across suitable healthcare environments. Manufacturers will increasingly emphasize analytical traceability and reliable performance under routine clinical conditions. Opportunities will remain significant in healthcare systems seeking more convenient chronic disease monitoring.
North America will remain an important market for advanced point-of-care HbA1c systems, while Europe and Asia-Pacific support demand through established healthcare networks and expanding diagnostic accessibility. Abbott, Siemens, Roche, Bio-Rad, EKF Diagnostics, Sinocare (PTS Diagnostics) and other supplied companies will compete through testing technology, distribution and clinical support. Future product development will focus on accurate results, manageable consumables and integration with healthcare information systems. Sustainable market expansion will depend on appropriate regulatory authorization, reliable operator training and consistent clinical performance across different testing locations.
POC HbA1C Testing Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 767.39 Million in 2026 |
|
|
Market Size Value By |
USD 2139.55 Million by 2035 |
|
|
Growth Rate |
CAGR of 12.07% from 2026-2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Frequently Asked Questions
The global POC HbA1C Testing Market is expected to reach USD 2139.55 Million by 2035.
The POC HbA1C Testing Market is expected to exhibit a CAGR of 12.07% by 2035.
Abbott, Siemens, Roche, Bio-Rad, GREEN CROSS MEDIS, Trinity Biotech, HUMAN Diagnostics, Sinocare (PTS Diagnostics), Erba Diagnostics, EKF Diagnostics, OSANG Healthcare, SD Biosensor
In 2026, the POC HbA1C Testing Market value will reach at USD 767.39 Million.